


## Contents


<b>Supplementary Figures</b> .....	2
Supplementary Figure 1. ZIKV stock production.....	2
Supplementary Figure 2. Frequency of ZIKV E-reactive memory B cells identified for previously infected subjects.....	3
Supplementary Figure 3. Rapid RTCA screening for neutralizing activity of mAbs to identify lead candidates for <i>in vivo</i> protection studies.....	4-5
Supplementary Figure 4. Large-scale production and qualification of ZIKV-753 and ZIKV-893 RNAs.....	6
<b>Supplementary Tables</b> .....	7
Supplementary Table 1. Research subject demographics and ZIKV exposure history.....	7
Supplementary Table 2. Summary of antibody discovery approaches and characterization assays .....	8-12
Supplementary Table 3. Inferred antibody germline genes and variable region analysis of selected lead candidates that tested <i>in vivo</i> in mice.....	13
Supplementary Table 4. Efficacy of mAb-encoding RNA formulation and IgG protein treatment against ZIKV <i>in vivo</i> in mice.....	14
<b>Supplementary References</b> .....	15

## Supplementary Figures






### Supplementary Figure 1. ZIKV stock production.

**(a)** Propagation of ZIKV Dakar MA was assessed in a panel of immortalized cell lines. Viral growth was assessed by qRT-PCR from clarified cell culture supernatants harvested 72 hrs after virus inoculation. Data represented a single measurement from one experiment. **(b)** Propagation of ZIKV Dakar MA in Vero cells grown in roller bottles was determined at various FBS concentrations. Viral growth was measured by FFA of culture supernatants. Data represented mean  $\pm$  SD values of technical duplicates from a single experiment. **(c)** Concentration and inactivation of ZIKV Dakar MA was assessed in indicated fractions obtained after ultra-centrifugation of infected Vero cell culture supernatant (72 hrs after virus inoculation), as well as following treatment with hydrogen peroxide. Viral titer was measured by FFA. LOD was 100 FFU/mL. Data represented a single measurement from one experiment.




**Supplementary Figure 2. Frequency of ZIKV E-reactive memory B cells identified from previously infected subjects. (a)** Flow cytometric identification of target-specific B cells after labeling of magnetically enriched total B cells with phenotyping antibodies, biotinylated ZIKV E protein, and fluorochrome-conjugated streptavidin (see **Methods**). **(b)** Percent (%) of ZIKV E-reactive B cells from each subject was assessed by analytical flow cytometry using an iQue Plus Screener flow cytometer. Up to 10,000 enriched B cells were analyzed for each subject. Plots represent viable CD19<sup>+</sup>IgM<sup>-</sup>IgD<sup>-</sup> population and are gated as in **a**. Subject with no history for ZIKV exposure served as a control for background E protein staining, and subject #1001 described previously<sup>1</sup> served as a positive control for E protein staining (blue background plots). Seven subjects selected for ZIKV-specific mAb discovery are indicated with “\*” symbol.



**Supplementary Figure 3. Rapid RTCA screening for neutralizing activity of mAbs to identify lead candidates for *in vivo* protection studies.**

**(a)** Enlarged brightfield image (right) of shadowed electrodes and adherent Vero cells (with or without virus to visualize CPE) from single wells of 96-well E-plates (left). Single well Vero cell images are representative of five or more images taken for each condition. **(b)** Representative sensograms for Vero cells that were inoculated with ZIKV (Brazil strain) in the presence of fully neutralizing ZIKV-117 (magenta) and partially neutralizing ZIKV-116 (green). mAbs ZIKV-117 and ZIKV-116 were described previously<sup>1</sup>. Uninfected cells (blue) and infected cells without antibody addition (red) served as controls for intact monolayer and full CPE, respectively. Data represented mean  $\pm$  SD values of technical duplicates. **(c)** Example sensograms from one 96-well E-plate analysis showing rapid identification of mAbs that fully neutralize ZIKV (indicated with grey arrows). Neutralization was assessed for 1:25 micro-scale purified mAbs dilution (see **Methods**) using ZIKV Brazil strain. Plates were measured continuously for 45 hrs after applying virus and mAb mixtures to the Vero cell monolayers.



**Supplementary Figure 4. Large-scale production and qualification of ZIKV-753 and ZIKV-893 RNAs.**

**(a)** Quality and purity of large-scale produced RNA. Following large-scale *in vitro* transcription (IVT) and capping, ZIKV-752 and ZIKV-893 RNA were purified and concentrated by Capto Core chromatography and tangential flow filtration, prior to sterile-filtration and storage at  $-80^{\circ}\text{C}$ . ZIKV-752 and -893 RNA were analyzed by denaturing gel electrophoresis as well as silver-stain SDS-PAGE to assess quality and purity of post-processed RNA. The experiment was repeated independently at least three times and for several post-processed RNA preparations with similar results in addition to ZIKV-752 and -893 analysis shown here **(b)** Human IgG concentration in mouse plasma after RNA delivery. To verify function, processed ZIKV-752 and -893 were formulated with NLC, and  $40\ \mu\text{g}$  of formulation was injected intramuscularly into C57BL/6 mice ( $n=5$  mice per group). Blood was collected on days 3, 5, and 7, and concentrations of total human IgG protein were determined in serum by ELISA using recombinant ZIKV-752 and -893 mAbs to generate a standard curve. Dots show measurements from individual mice and mean  $\pm$  SD values are shown.

## Supplementary Tables

**Supplementary Table 1. Research subject demographics and ZIKV exposure history.**

Subject ID	Gender	Age	Ethnicity	ZIKV strain lineage*	Year infected	Country in which infection occurred	PBMCs collection timepoint
1001**	Male	41	Hispanic or Latino	Asian	2015	Brazil	7 months after infection
1011**	Female	25	Not Hispanic or Latino	Asian	2016	Haiti	March 2016
1046**	Female	58	Hispanic or Latino	Asian	2016	Dominican Republic	>90 days after infection
1054**	Female	62	Not Hispanic or Latino	Asian	2016	Puerto Rico	>90 days after infection
1057**	Male	40	Not Hispanic or Latino	Asian	2016	Nicaragua	5 weeks and six months post 1st symptom
1060**	Female	35	Not Hispanic or Latino	Asian	2016	Guatemala	>90 days after infection
1064**	Male	19	Not Hispanic or Latino	Asian	2016	Guatemala	>90 days after infection
1002	Female	42	Not Hispanic or Latino	Asian	2016	Mexico	>90 days after infection
1010	Female	25	Not Hispanic or Latino	Asian	2016	Haiti	>90 days after infection
1012	Female	19	Not Hispanic or Latino	Asian	2016	Haiti	>90 days after infection
1016	Female	21	Not Hispanic or Latino	Asian	2016	Haiti	>90 days after infection
269***	Male	58	Not Hispanic or Latino	NA	NA	NA	NA

\* - The subjects likely had been infected with a strain of Asian lineage of ZIKV, since they contracted the disease during the recent outbreak in South America. Flavivirus immune status at the time of ZIKV infection for these subjects is unknown. \*\* - subjects selected for ZIKV-specific mAb discovery. \*\*\* -uninfected control subject. NA – not applicable.

Supplementary Table 2. Summary of antibody discovery approaches and characterization assays.

Clone ID	*Starting method to isolate mAb	Microscale-purified mAb analysis to identify candidates for <i>in vivo</i> study															Analysis of mid-scale purified mAb that were used for <i>in vivo</i> studies		
		**Purified mAb yield (µg)	***ELISA binding O.D. 450 nm to ZIKV E2 assessed for 1:10 CHO culture supernatant dilution	***ELISA binding O.D. 450 nm to ZIKV E2 assessed for 1:100 purified mAb dilution	****Antigenic site determined by competition binding with reference mAb	ZIKV Brazil neutralization assessed by RTCA for 1:10 CHO culture supernatant dilution (+/-)	ZIKV Brazil neutralization assessed by RTCA for 1:25 purified mAb dilution (+/-)	ZIKV Dakar neutralization assessed by FRIT for 1:16 purified mAb dilution (+/-)	ZIKV Brazil neutralization assessed by FRIT for 1:16 purified mAb dilution (+/-)	ZIKV Dakar neutralization assessed by RTCA for neutralizing mAbs	ZIKV Brazil neutralization assessed by RTCA for neutralizing mAbs	ZIKV Dakar IC50 (ng/mL) assessed by RTCA for purified mAbs	ZIKV Brazil IC50 (ng/mL) assessed by FRIT for purified mAbs	ZIKV Dakar IC50 (ng/mL) assessed by FRIT for purified mAbs	ZIKV Brazil IC50 (ng/mL) assessed by FRIT for purified mAbs	****ADCP assessed for purified mAbs (Z-score)	****ADNP assessed for purified mAbs (Z-score)	****ADCO assessed for purified mAbs (Z-score)	ZIKV Dakar IC50 (ng/mL) assessed by RTCA for purified mAbs
30v17 vsm1	-	230	3.4	4.2	NO	+	+	+	+	+	42	7	34	34	2.3	2.0	2.0	NO	NO
30v40	NO	21	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.4	0.2	NO	NO
30v46	NO	4	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.3	NO	NO
30v47	NO	4	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v48	NO	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.4	0.2	NO	NO
30v50	NO	14	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v51	NO	4	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v42	NO	12	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.6	0.4	0.2	NO	NO
30v43	NO	12	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.6	0.4	0.2	NO	NO
30v44	NO	14	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.6	0.4	0.2	NO	NO
30v47	NO	8	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.3	0.2	NO	NO
30v48	NO	25	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.3	0.2	NO	NO
30v49	NO	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.6	0.4	0.2	NO	NO
30v45	NO	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.3	0.2	NO	NO
30v41	NO	104	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v42	NO	120	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v43	NO	111	3.0	4.2	116	+	+	+	+	+	NO	NO	1,212	0.3	0.3	0.2	>3,000	305	
30v44	NO	48	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v45	NO	17	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v46	NO	8	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v47	NO	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v48	NO	12	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v49	Sub-panel 1	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v42	NO	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.2	0.2	0.2	NO	NO
30v43	NO	1	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.2	0.2	0.2	NO	NO
30v44	NO	12	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.2	0.2	0.2	NO	NO
30v45	NO	12	3.7	4.2	FL	-	-	-	-	-	NO	NO	NO	NO	1.4	1.2	0.2	112	308
30v47	Sub-panel 2	200	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v48	NO	20	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v49	Sub-panel 1	27	3.1	4.1	Unknown	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v40	NO	40	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v41	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v42	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v43	Sub-panel 1	1	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v46	NO	6	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v47	NO	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v48	NO	12	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.4	0.4	0.2	NO	NO
30v49	Sub-panel 1	25.5	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v42	NO	11	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.3	0.3	0.2	NO	NO
30v43	NO	40	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v44	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v45	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v46	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v47	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v48	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v49	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v40	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v41	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v42	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v43	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v44	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v45	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v46	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v47	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v48	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v49	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v40	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v41	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v42	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v43	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v44	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v45	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v46	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v47	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v48	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v49	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v40	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v41	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v42	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v43	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v44	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v45	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v46	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v47	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v48	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v49	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v40	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v41	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v42	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v43	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v44	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v45	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v46	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v47	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v48	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v49	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v40	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v41	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v42	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v43	NO	10	-	-	NO	-	-	-	-	-	NO	NO	NO	NO	0.5	0.5	0.2	NO	NO
30v44	NO	10	-	-	NO	-	-												









**Supplementary Table 2 continued. Summary of antibody discovery approaches and characterization assays.**

ZIKV-001	Sub-panel 1	12	3.2	1.2	ND	+	ND	+	+	+	+	ND	97	ND	1,666	0.0	1.1	2.1	ND	ND
ZIKV-002	Sub-panel 1	4	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	2.2	2.4	2.4	ND	ND
ZIKV-003	Sub-panel 1	24	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	2.3	2.4	2.4	ND	ND
ZIKV-004	Sub-panel 1	42	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	2.3	2.4	2.4	ND	ND
ZIKV-005	Sub-panel 1	42	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	2.3	2.4	2.4	ND	ND
ZIKV-006	Sub-panel 1	48	4.0	3.5	117	+	ND	+	+	+	+	42	75	334	294	1.0	2.1	2.1	129	138
ZIKV-007	Sub-panel 1	24	3.8	2.2	Unknown	+	ND	+	+	+	+	382	202	1,820	534	0.5	0.9	1.4	1,100	426
ZIKV-008	Sub-panel 1	24	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	2.3	2.4	2.4	ND	ND
ZIKV-009	Sub-panel 1	12	4.0	3.6	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	2.0	2.1	2.2	ND	ND
ZIKV-010	Sub-panel 1	24	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	1.5	0.9	0.9	ND	ND
ZIKV-011	Sub-panel 1	24	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	1.4	2.0	2.0	ND	ND
ZIKV-012	Sub-panel 1	24	-	-	ND	-	ND	-	-	ND	ND	ND	ND	ND	ND	1.4	2.0	2.0	ND	ND

\* mAbs were isolated by indicated B cell labeling and sorting approach. Sub-panel 1 - labeling with biotinylated E; Sub-panel 2 - labeling with intact E followed by detection with fusion loop-specific mAb; labeling and detection is the same as for Sub-panel 2 and sorting of high-affinity population only. ND – not determined when cells were pooled from different sorting approaches for the analysis.

\*\* Total volume of each purified mAb was 100 µL. The limit of IgG detection was 5 µg/mL, and the amount mAbs that could not be detected by the assay used is indicated as <0.5 µg.

\*\*\* O.D. 450 nm of 0.3 (three-fold over the negative control) was set as a threshold for mAb reactivity, and non-reactive mAbs are indicated with "-" symbol.

\*\*\*\* mAbs of known epitope specificity included ZIKV-88 (recognizes FL), ZIKV-116 (recognizes DIII), and ZIKV-117 (recognizes DII) as from a previous report<sup>1</sup>.

\*\*\*\*\* Each mAb was tested in a single dilution from micro-scale purified samples and mAb concentration was not normalized. Z-score ( $z$ ) =  $(x-\mu)/\sigma$ , where  $x$  is raw score that determined as described in the **Methods**,  $\mu$  is the mean of the population, and  $\sigma$  is the standard deviation of the population.

ND - not determined. "-" symbol indicates neutralizing activity was not detected at the highest tested mAb concentration, 3,000 ng/mL.

**Supplementary Table 3. Inferred antibody germline genes and variable region analysis of selected lead candidates that tested *in vivo* in mice.**

mAb clone	Heavy chain variable gene sequence					Light chain variable gene sequence			
	V-gene and allele	D-gene and allele	J-gene and allele	CDR3 amino acid sequence	Percent identity of germline	V-gene and allele	J-gene and allele	CDR3 amino acid sequence	Percent identity of germline
ZIKV-423	3-23*01	3-10*01	4*02	AKDRTSGGFGELFKH	89	1-5*03	1*01	QHYHSYPWT	95
ZIKV-434	3-48*03	3-3*01	4*02	ARDRYDFWSGDPMGYFDY	92	1-5*03	1*01	QQYNRGSWT	94
ZIKV-518	2-5*01	6-13*01	5*02	AHTVLVSRNWYVLNWFDP	97	2-14*01	1*01	QVWDDSSDQWV	98
ZIKV-608	3-23*04	3-10*01	4*02	AKDRPSLGVGELYDY	91	1-5*03	J1*01	QQYNSYPWT	100
ZIKV-609	3-23*01	6-19*01	4*02	AKDHPQWLGSHE	94	3-21*02	J1*01	QVWDSTRDQYV	98
ZIKV-624	3-11*05	2-2*02	6*03	ARDRLTYPPYHYMDV	98	1-44*01	J3*02	AAWDDSLNGRV	98
ZIKV-635	3-30*18	6-13*01	3*02	AKDSAGRWRQQLSAGI	97	2-28*01	J1*01	MQALQTPWT	99
ZIKV-652	3-23*01	6-19*01	4*02	AKVIDQWLGFYD	97	3-21*02	J3*02	QVWDDSSDQWV	99
ZIKV-668	3-49*05	3/15-3a*01	5*02	TRDFNDFWTGHHPNWFDP	98	1-39*01	1*01	QQSYSIPRT	99
ZIKV-681	3-23*04	3-10*01	4*02	AKDRVVRGVGENLDH	89	1-27*01	1*01	QKYNSVPWT	92
ZIKV-682	3-30*18	1-26*01	4*02	AKEREWVVRDGGFDY	97	3-21*02	2*01	QVWHSNTDHVV	98
ZIKV-684	3-73*01	3-22*01	4*02	IRQGGYSESEFDY	96	1-40*01	2*01	QSYDSSLTVHVV	98
ZIKV-752	1-8*01	6-19*01	6*02	ARVTSGSSYGTTYYYAMDV	96	1-47*01	3*02	ASWDDRLSGSWV	97
ZIKV-869	3-13*01	2-2*01	6*02	ARVAHHSEYHLLYMPHGMDV	96	2-23*01	3*02	CSYTDNSPYVL	97
ZIKV-893	3-30*18, 3-30-5*01	3-16*02	4*02	AKVGSHYYDIWGTYYRRFDY	97	1-39*01	3*01	QQYGSSPPVT	100
ZIKV-922	3-23*04	3-10*01	4*02	AKDRPSRGGVGEYDY	92	1-5*03	J1*01	QQYLSYPWT	95
ZIKV-940	4-59*01	6-19*01	4*02	ARDCASGWDGCFD	96	1-44*01	1*01	AAWDDSLNGYV	99
ZIKV-980	3-30*04	6-19*01	6*02	VRDRKVAGQMIRHGMDV	96	8-61*01	3*02	TLYMGSGISV	98
ZIKV-1006	3-33*01	3-10*01	3*02	ARVGVGADDAFDI	94	3-21*02	3*02	QVWDSNSDHGV	97
ZIKV-1007	3-9*01	4-17*01	4*02	AKTKAYGDFHFDY	97	3-21*02	2*01	QLWDTSSNPHVV	98

**Supplementary Table 4. Efficacy of mAb-encoding RNA formulation and IgG protein treatment against ZIKV *in vivo* in mice.**

mAb clone	Prophylactic RNA treatment, # survived/treated mice (% survival)	IgG protein treatment, # survived/treated mice (% survival)							
		Prophylaxis dose per mouse, d-1					Treatment dose per mouse, 1 dpi		
		70 µg	9 µg	4.5 µg	2 µg	1 µg	9 µg	4.5 µg	
ZIKV-423	2/5 (40%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-434	5/5 (100%)	1/5 (20%)	ND	ND	ND	ND	ND	ND	ND
ZIKV-518	0/5(0%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-608	0/5 (0%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-609	5/5 (100%)	ND	2/5 (40%)	ND	ND	ND	ND	ND	ND
ZIKV-624	5/5 (100%)	ND	3/5 (60%)	ND	ND	ND	ND	ND	ND
ZIKV-635	5/5 (100%)	5/5 (100%)	5/5 (100%)	ND	ND	ND	ND	ND	ND
ZIKV-652	5/5 (100%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-668	5/5 (100%)	4/5 (80%)	5/5 (100%)	ND	ND	ND	ND	ND	ND
ZIKV-681	2/5 (40%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-682	4/5 (80%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-684	5/5 (100%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-752	4/5 (80%)	5/5 (100%)	11/14 (79%)	7/9 (78%)	2/4 (50%)	2/4 (50%)	3/5 (60%)	3/5 (60%)	3/5 (60%)
ZIKV-869	2/5 (40%)	ND	4/5 (80%)	ND	ND	ND	ND	ND	ND
ZIKV-893	5/5 (100%)	5/5 (100%)	14/14 (100%)	4/4 (100%)	4/4 (100%)	0/4 (0%)	5/5 (100%)	4/5 (80%)	4/5 (80%)
ZIKV-922	0/5 (0%)	ND	ND	ND	ND	ND	ND	ND	ND
ZIKV-940	5/5 (100%)	ND	9/13 (69%)	3/4 (75%)	2/4 (50%)	2/4 (50%)	5/5 (100%)	4/5 (80%)	4/5 (80%)
ZIKV-980	1/5 (20%)	ND	0/5 (0%)	ND	ND	ND	ND	ND	ND
ZIKV-1006	0/5 (0%)	ND	1/5 (20%)	ND	ND	ND	ND	ND	ND
ZIKV-1007	0/5 (0%)	ND	ND	ND	ND	ND	ND	ND	ND
<b>ZIKV-117 control</b>	5/5 (100%)	ND	14/14 (100%)	9/9 (100%)	3/4 (75%)	0/4 (0%)	4/5 (80%)	5/5 (100%)	5/5 (100%)
<b>FLU-5J8 control</b>	1/5 (0%)	2/5 (40%)	0/5 (0%)	ND	ND	ND	1/5 (20%)	1/5 (20%)	1/5 (20%)
<b>PBS control</b>	1/5 (0%)	ND	ND	1/4 (25%)	1/4 (25%)	1/4 (25%)	ND	ND	ND

**References for Supplementary Information.**

1. Sapparapu, G. *et al.* Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. *Nature* **540**, 443-447 (2016).